Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Down 6.8% After Analyst Downgrade

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) fell 6.8% during trading on Friday after Barclays lowered their price target on the stock from $58.00 to $56.00. Barclays currently has an overweight rating on the stock. Collegium Pharmaceutical traded as low as $45.58 and last traded at $45.47. 144,903 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 477,033 shares. The stock had previously closed at $48.78.

Several other research analysts have also commented on COLL. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th. Truist Financial set a $55.00 target price on Collegium Pharmaceutical in a report on Wednesday. Needham & Company LLC boosted their price target on Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price target (up previously from $46.00) on shares of Collegium Pharmaceutical in a report on Friday. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $52.80.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 30,000 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the completion of the transaction, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at $5,133,813.51. This trade represents a 19.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the sale, the director directly owned 52,629 shares of the company’s stock, valued at $2,475,141.87. The trade was a 6.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 51,250 shares of company stock valued at $2,235,352 over the last ninety days. Corporate insiders own 2.51% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Rubric Capital Management LP grew its position in shares of Collegium Pharmaceutical by 5.3% in the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after acquiring an additional 157,743 shares in the last quarter. Emerald Advisers LLC raised its position in shares of Collegium Pharmaceutical by 1.3% during the 2nd quarter. Emerald Advisers LLC now owns 837,549 shares of the specialty pharmaceutical company’s stock valued at $24,766,000 after acquiring an additional 11,074 shares in the last quarter. Geode Capital Management LLC lifted its stake in Collegium Pharmaceutical by 1.9% during the second quarter. Geode Capital Management LLC now owns 780,243 shares of the specialty pharmaceutical company’s stock worth $23,075,000 after purchasing an additional 14,709 shares during the last quarter. Millennium Management LLC boosted its holdings in Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares during the period. Finally, Bank of America Corp DE boosted its holdings in Collegium Pharmaceutical by 13.8% in the second quarter. Bank of America Corp DE now owns 514,807 shares of the specialty pharmaceutical company’s stock worth $15,223,000 after purchasing an additional 62,274 shares during the period.

Collegium Pharmaceutical Trading Down 6.8%

The stock has a market cap of $1.44 billion, a P/E ratio of 28.31 and a beta of 0.60. The firm’s 50 day simple moving average is $46.04 and its two-hundred day simple moving average is $38.38. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The business had revenue of $135.55 million during the quarter. As a group, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.